XML 23 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
 [1]
Current assets:    
Cash and cash equivalents $ 135,212 $ 151,686
Short-term investments 214,044 268,117
Trade and other receivables 43,125 40,444
Inventory, net 5,425 3,338
Prepaid expenses and other current assets 4,433 5,416
Total current assets 402,239 469,001
Long-term investments 26,413 55,601
Long-term restricted cash and investments 4,650 4,150
Property and equipment, net 18,684 2,071
Goodwill 63,684 63,684
Other long-term assets 862 1,232
Total assets 516,532 595,739
Current liabilities:    
Accounts payable 7,037 6,565
Accrued compensation and benefits 15,555 20,334
Accrued clinical trial liabilities 14,680 14,131
Accrued collaboration liabilities 7,919 2,046
Convertible notes 0 109,122
Term loan payable 0 80,000
Current portion of deferred revenue 31,255 19,665
Other current liabilities 21,225 16,923
Total current liabilities 97,671 268,786
Long-term portion of deferred revenue 253,663 237,094
Other long-term liabilities 16,687 541
Total liabilities 368,021 506,421
Commitments
Stockholders’ equity    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 293,727,630 and 289,923,798 at June 30, 2017 and December 31, 2016, respectively 294 290
Additional paid-in capital 2,097,379 2,072,591
Accumulated other comprehensive loss (119) (416)
Accumulated deficit (1,949,043) (1,983,147)
Total stockholders’ equity 148,511 89,318
Total liabilities and stockholders’ equity $ 516,532 $ 595,739
[1] The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements as of that date.